Consistent with this study, overlaying NeoAg therapy with pembrolizumab or nivolumab (anti-PD-1) treatment of patients with melanoma does not appear to negatively impact vaccine-induced NeoAg-specific responses, but rather preserves them while also supporting epitope spreading to novel CD8+ T cell reactivities (52, 53, 72). This evidence concerns the gene CD8A and melanoma.